All section Close
Image Credits: James Dyson Award - Project EpiSHOT
'EpiSHOT': Unique Innovation By IISc Bangalore Students To Deliver Emergency Medication Earns Them James Dyson Award
Writer: Apoorva Chakrayat
She is a mass communication undergrad student at Makhanlal Chaturvedi National University of Journalism and Communication.
Karnataka, 8 Nov 2022 12:52 PM GMT
Editor : Jayali Wavhal |
She writes about gender issues, human interest, and environment.
Creatives : Apoorva Chakrayat
She is a mass communication undergrad student at Makhanlal Chaturvedi National University of Journalism and Communication.
The two engineering students will receive the prize money of Rs. 4.6 lakh and the opportunity to represent India worldwide, where Sir James Dyson will choose the eventual winners. According to the duo, their innovation is a safe and cost-efficient alternative for the use of emergency medicines.
Arjun and Krishnan, two engineering students from the Indian Institute of Sciences in Bangalore, invented "EpiSHOT," a single hand-operated autoinjector that can deliver emergency medication intramuscularly or subcutaneously to treat life-threatening conditions like anaphylaxis (or an allergic reaction). It can also be reloaded and sterilised for reuse within two minutes after the initial use.
The innovation has made them the national winners of the James Dyson Award for the year 2022, which is given by the James Dyson Foundation to support budding engineers. The duo will get the prize money of Rs. 4.6 lakh and get to represent India in the worldwide round, where Sir James Dyson himself will choose the eventual winners.
Safe And Cost-Efficient
Arjun and Krishnan will further modify EpiSHOT for commercial use. The move will lower the device's price while improving the manufacturability, dependability, and portability, according to The Indian Express.
Krishnan informed that more than 100 tests on tissue phantoms were conducted to guarantee the complete safety of use. The group is searching for possible pharmaceutical collaborators to apply the technology for applications such as allergy and other medication delivery.
Arjun said, "India does not currently have an immediate solution to anaphylaxis, which indicates a predominance for the age range 20 to 40 years. There is still a bigger need for a secure and affordable solution because of current market monopolies, the high cost of single-use autoinjectors, and safety concerns for self-use. EpiSHOT aims to bridge this gap ."
They added that the James Dyson Award is a significant accomplishment and will serve as a springboard for getting EpiSHOT recognised on higher stages.
Also Read: Election Commission Launches App For People With Disabilities
Must Reads
We are an independent and public-spirited digital media platform for Indian millennials. We report news and issues that matter as well as give you the opportunity to take action.
